<![CDATA[Janssen Submits to the EMA for Talquetamab]]>Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

January 03, 2023 04:25 ET ' Source: Janssen Pharmaceutica NV

Link Preview Image
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

BEERSE, BELGIUM, Jan. 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a...

favicon

GlobeNewswire News Room (www.globenewswire.com)

]]>https://dev.proinvestor.com/forum/topic/444633/janssen-submits-to-the-ema-for-talquetamabRSS for NodeSun, 28 Jun 2026 00:10:15 GMTTue, 03 Jan 2023 08:44:55 GMT60